Brain metastases are a common and devastating consequence of disease progression in
patients with non–small cell lung cancer (NSCLC). The epidermal growth factor receptor …

Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …

Background Lung cancer is the leading cause of cancer-related death worldwide. Up to 85%
of lung cancer is non-small cell lung cancer (NSCLC) and most patients present with …

Objectives Central nervous system (CNS) metastases are common complications in
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …

Background Osimertinib shows pronounced efficacy for EGFR mutation–positive non–small
cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases …

Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically
changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard …

Abstract Background Approximately 20%–30% of patients (pts) with EGFR mutation-positive
NSCLC present with CNS metastases at the time of diagnosis of advanced disease. CNS …

Background This study was designed to investigate the difference between brain
metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced …

The brain is one of the most common sites for lung adenocarcinoma metastasis, which are
found in almost 20-30% of patients with the disease (1). These patients have poor median …

Brain metastasis from non-small cell lung cancer (NSCLC) with epidermal growth factor
receptor (EGFR) mutations is a hot research topic, but also a difficulty in targeted NSCLC …